Mirum Pharmaceuticals, Inc. $MIRM Shares Newly Purchased by Secure Asset Management LLC

Secure Asset Management LLC bought a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 3rd quarter, Holdings Channel reports. The fund bought 52,246 shares of the company’s stock, valued at approximately $4,466,000.

Other institutional investors also recently modified their holdings of the company. Jupiter Topco LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $691,672,000. BlackRock Inc. acquired a new position in Mirum Pharmaceuticals in the second quarter valued at approximately $513,945,000. William Blair Investment Management LLC acquired a new position in Mirum Pharmaceuticals in the second quarter valued at approximately $164,453,000. Janus Henderson Group PLC lifted its holdings in Mirum Pharmaceuticals by 14.5% in the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after buying an additional 880,505 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in Mirum Pharmaceuticals in the second quarter valued at approximately $78,434,000.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $82.24 on Tuesday. Mirum Pharmaceuticals, Inc. has a twelve month low of $63.23 and a twelve month high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 2.74. The company’s fifty day moving average is $92.72 and its 200-day moving average is $100.65.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The firm had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. Mirum Pharmaceuticals’s quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.12) EPS. On average, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.32 earnings per share for the current year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total value of $2,960,400.00. Following the completion of the sale, the chief executive officer directly owned 194,440 shares in the company, valued at $19,187,339.20. This represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the sale, the chief financial officer directly owned 36,355 shares in the company, valued at approximately $3,631,864.50. This represents a 14.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 98,499 shares of company stock worth $9,797,834. Corporate insiders own 8.32% of the company’s stock.

Analyst Ratings Changes

MIRM has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Wall Street Zen downgraded Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, September 6th. Citigroup raised their price target on Mirum Pharmaceuticals from $160.00 to $184.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. HC Wainwright raised their price target on Mirum Pharmaceuticals from $195.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Finally, Morgan Stanley lifted their price objective on Mirum Pharmaceuticals from $137.00 to $152.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $147.88.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.